Related Experiment Video
Updated: May 30, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Fabry disease and early stroke
1Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Insights
Fabry disease, a genetic disorder, causes serious health issues like strokes and kidney failure. Early enzyme replacement therapy and stroke prevention are crucial for both males and females with Fabry disease.
Area of Science:
- Genetics and rare diseases
- Neurology
- Metabolic disorders
Background:
- Fabry disease is an X-linked lysosomal storage disorder caused by alpha-galactosidase A deficiency.
- It leads to accumulation of globotriaosylceramide (GL-3) in vascular endothelium, causing organ damage.
- Symptoms range from childhood acroparesthesias to adult-onset renal failure, cardiac hypertrophy, and strokes.
Purpose of the Study:
- To review the natural history and management of Fabry disease.
- To highlight the importance of considering Fabry disease in young stroke populations.
- To emphasize the role of enzyme replacement therapy and prophylactic stroke measures.
Main Methods:
- Literature review of Fabry disease natural history, clinical manifestations, and treatment options.
- Analysis of existing data on stroke incidence and risk factors in Fabry patients.
- Discussion of current therapeutic strategies, including enzyme replacement and secondary stroke prevention.
Main Results:
- Fabry disease can cause strokes and other severe complications in both males and females, even at a young age.
- White matter lesions on MRI are observed in affected individuals.
- Enzyme replacement therapy is safe and effective for both genders, but long-term data on mortality and morbidity are still being gathered.
Conclusions:
- Screening young stroke patients for Fabry disease should be considered.
- Liberal use of stroke prophylactic therapy, including lifestyle modifications and management of comorbidities, is recommended for all Fabry patients.
- Ongoing studies will provide further insights into the benefits of screening and treatment.
Abstract:
Fabry disease, an X-linked lysosomal storage disorder, results from deficient activity of the enzyme α-galactosidase A. Affected males with the classic phoenotype have acroparaesthesias, hypohidrosis, and corneal opacities in childhood and develop renal failure, cardiac hypertrophy or strokes in the third to fifth decade of life. Some female heterozygotes are asymptomatic, some as severely affected as males. The natural history of Fabry patients includes transitory cerebral ischaemia and strokes, even in very young persons of both genders. The mechanism is partly due to vascular endothelial accumulation of GL-3. White matter lesions on MRI occur. Both males and females can be safely treated with enzyme replacement; and thus screening for Fabry disease of young stroke populations should be considered. There are, however, no hard data of treatment effect on mortality and morbidity. The analyses of results from ongoing studirs will add to the decision on whether or not to screen young stroke patients for Fabry disease. Finally, stroke prophylactic therapy should be used liberally in patients of both genders with verified Fabry disease. This includes primary prevention such as lifestyle counseling, targeting blood pressure, managing atrial fibrillation, diabetes mellitus, hyperlipidaemia, and ASA.
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Rheumatic Heart Disease I: Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Hemorrhagic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Dementia l: Introduction

